[The post partum administration of quingestanolacetate 0.3 mg as oral contraceptive (author's transl)].
Quingestanolacetate (0.3 mg daily), as from the second week post partum was given to 13 women for a total of 111 therapeutic cycles of 28 days. In addition to clinical follow up, 8 women were subjected to serial pregnanediol determinations in the night urine every other day for a total of 45 cycles. One woman became pregnant in the 5th therapeutic cycle, demonstrating an insufficient contraceptive effect of this minipill. The only major side effect was the occurrence of irregular episodes of bleeding during the first 3 therapeutic cycles. With increasing duration of the administration of this drug, the vaginal bleeding settled down to approximately 7 days per 28 days. When pregnanediol serial determinations were started in the 4th to 6th therapeutic cycle post partum, 6 out of 8 women showed ovulatory cycles. In the two remaining patients ovulatory cycles were observed in the 7th and 10th therapeutic cycle, respectively. Of 45 cycles in which control pregnanediol serial determinations had been undertaken, 11 (25%) were anovulatory, 21 (46%) showed a normal ovulatory excretion pattern and 13 (29%) showed severe luteal insufficiency. An insufficiency of luteal function appears to be partially responsible for the contraceptive effect of this minipill.
D000328:Adult; D003267:Contraception; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000139:chemically induced; D009649:Norpregnadienes / Q000008:administration & dosage* / Q000009:adverse effects; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy; D011276:Pregnanediol / Q000652:urine; D013997:Time Factors
D009649:Norpregnadienes; D011276:Pregnanediol
Die kontinuierliche postpartale Verabreichung von Quingestanolazetat 0,3 mg als Kontrazeptivum